Bernstein Forecasts India’s Biopharma Market to Hit $195 Bn by 2035 on Innovation Surge

Why It Matters

The projected $195 bn market size positions India as one of the world’s fastest‑growing biopharma hubs, offering investors a rare blend of scale, cost advantage, and emerging‑market growth. A successful transition to high‑margin, innovation‑driven products could diversify India’s export basket, reduce reliance on low‑cost generics, and strengthen the country’s trade balance. For emerging‑market portfolios, the forecast provides a concrete catalyst for reallocating capital toward health‑care, a sector traditionally under‑weighted in such markets. The emphasis on AI‑enabled efficiency and quality upgrades also signals that Indian firms are moving up the value chain, potentially narrowing the gap with established global players and creating new partnership opportunities.

Key Takeaways

• Bernstein projects India’s biopharma market to reach $195 bn by 2035, a four‑fold increase.
• Six niche “rainmaker” therapies—505(b)(2) NDAs, orphan drugs, drug‑device combos, repurposed drugs, metabolic peptides, and RNA/cellular therapies—could add $70‑75 bn.
• Top outperform picks: Zydus Lifesciences, Lupin, Sun Pharma; underperform: Biocon, Mankind Pharma.
• Gen‑AI adoption expected to lift profit margins by 3‑4 percentage points, with 70 % of gains from R&D and operations.
• Bernstein sees valuations for its picks well below ten‑year averages, offering a pricing edge.

Pulse Analysis

Bernstein’s bullish stance reflects a broader re‑evaluation of India’s health‑care sector, which has historically been viewed through the lens of low‑cost generic production. The firm’s focus on high‑value, technology‑enabled therapies aligns with a global shift toward personalized medicine, where speed to market and manufacturing flexibility are paramount. By betting on AI‑driven R&D and a network of future‑ready plants, Bernstein anticipates that Indian firms will overcome traditional quality concerns that have limited export potential.

Historically, Indian biopharma growth has been tied to domestic demand and price‑sensitive generics. The new forecast suggests a pivot: companies that can master complex biologics and cell therapies could capture premium pricing and secure contracts with multinational pharma firms seeking cost‑effective manufacturing partners. This transition could also mitigate the impact of US and EU regulatory tightening on generic imports, providing a more resilient revenue base.

From an investment perspective, the forecast creates a compelling narrative for allocating capital to a sector that combines emerging‑market growth rates with the upside of high‑margin innovation. However, execution risk remains—success hinges on regulatory approvals for the identified rainmaker therapies, the ability to scale AI tools across fragmented R&D pipelines, and sustained policy support for quality upgrades. Investors should watch for early indicators such as FDA or CDSCO clearances for orphan drugs and the rollout of AI platforms in major Indian pharma labs. If these milestones are met, the $195 bn target could become a realistic benchmark for the next decade.